SELLAS Life Sciences is a pre-revenue clinical-stage biotech with a strengthened balance sheet—cash reached $138.4M in 2026Q2 versus $13.9M in 2024Q4—but persistent operating losses averaging roughly $7-9M per quarter underscore a high cash-burn profile. The c...
Price trend, volume and key moving averages
Trailing total returns as of 9/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.05-11.1% vs -$0.04 | — vs — |
Q2 2026 May 12, 2026 | -$0.05+16.7% vs -$0.06 | — vs — |
Q2 2026 Mar 19, 2026 | -$0.05+21.0% vs -$0.06 | — vs — |
Q4 2025 Nov 12, 2025 | -$0.06+5.3% vs -$0.06 | — vs — |
Power Metallic Defines High-Grade Maiden Resource at Lion Averaging ~3.9% CuEq, with >85% Indicated and Significant Expansion Potential
- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that three abstracts evaluating SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, in preclinical models of pancreatic ductal adenocarcinoma (PDAC) have been accepted for poster presentation at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) stock is trading higher on Thursday. Year-to-date, the stock has surged by around 300%.
SELLAS Life Sciences Group is a high-conviction buy ahead of the pivotal Phase 3 REGAL trial readout for GPS in AML. The unusually long REGAL trial timeline suggests GPS may be delivering a meaningful survival benefit in a high-unmet-need AML population. SLS is well-funded into 2027, with $138.3 million in cash and targeted spending aligned to upcoming binary catalysts.
Benchmark SLS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for SELLAS Life Sciences Group, Inc. (SLS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.96 | $2.6B | -55.84 | — | — | -66.88% | — | |
| $39.57 | $8.17B | -14.29 | — | -7585.86% | -69.59% | — | |
| $9.54 | $2.21B | 15.90 | 19.63% | 32.98% | 39.59% | — | |
| $75.44 | $2.49B | -7.75 | -43.89% | -287.84% | -37.99% | — | |
| $39.12 | $2.6B | -10.03 | -78.63% | -268385.71% | -52.36% | — | |
| $7.43 | $309.4M | -2185.29 | 10.37% | 69.76% | — | — |
SELLAS Life Sciences Group, Inc. (SLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
SELLAS Life Sciences Group, Inc. (SLS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jul 27, 2026·SEC
Jun 25, 2026·SEC
Get notified when SLS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SELLAS Life Sciences Group, Inc. (SLS) stock FAQ — growth, dividends, profitability & financials explained
SELLAS Life Sciences Group, Inc. (SLS) reported a net loss of $32.5M for fiscal year 2025.
SELLAS Life Sciences Group, Inc. (SLS) has a return on equity (ROE) of -66.9%. Negative ROE indicates the company is unprofitable.
SELLAS Life Sciences Group, Inc. (SLS) had negative free cash flow of $28.4M in fiscal year 2025, likely due to heavy capital investments.
